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Abstract: In this study, the inhibitory potential of 3-(5-nitrofuran-2-yl)prop-2-en-1-one derivatives
was evaluated against a panel of bacteria, as well as mammalian cell lines to determine their
therapeutic index. In addition, we investigated the mechanism of antibiotic action of the derivatives
to identify their therapeutic target. We discovered compound 2 to be an extremely potent inhibitor
of Mycobacterium tuberculosis H37Rv growth (MIC: 0.031 mg/L) in vitro, performing better than
the currently used first-line antituberculosis drugs such as isoniazid, rifampicin, ethambutol,
and pretomanid in vitro. Furthermore, compound 3 was equipotent to pretomanid against a
multidrug-resistant M. tuberculosis clinical isolate. The derivatives were selective and bactericidal
towards slow-growing mycobacteria. They showed low cytotoxicity towards murine RAW 264.7
and human THP-1 cell lines, with high selectivity indices. Compound 1 effectively eliminated the
intracellular mycobacteria in a mycobacteria-infected macrophage model. The derivatives were
assessed for their potential to inhibit mycobacterial arylamine N-acetyltransferase (NAT) and were
identified as good inhibitors of recombinant mycobacterial NAT, a novel target essential for the
intracellular survival of M. tuberculosis. This study provided hits for designing new potent and
selective antituberculosis leads, having mycobacterial NAT inhibition as their possible endogenous
mechanisms of action.
Keywords: tuberculosis; antibiotic resistance; 5-nitrofuran; arylamine N-acetyltransferase
1. Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis, ranks above HIV/AIDS in mortality and is
the leading cause of death due to a single infectious agent. In 2018, there were 1.5 million deaths due to
TB, and 10 million new cases were reported worldwide. The major hurdle in the successful treatment
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of TB is the emergence of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB)
strains. As per the drug resistance monitoring reports, 3.4% of new cases and 18% of previously treated
TB cases were MDR/rifampicin-resistant (RR)-TB cases, and 6.2% of the MDR-TB cases turned out to be
XDR-TB cases [1]. Thus, there is an urgent need to discover new drugs that possess a mechanism of
action different from the current drugs in TB therapy, which can effectively treat drug-resistant TB.
Mycolic acid is a major component of the mycobacterial cell wall and is crucial for the survival of
the bacteria, making it an important target in antituberculosis drug therapy [2]. Isoniazid, the first-line
antituberculosis drug, inhibits mycolic acid biosynthesis. However, isoniazid is inactivated by
mycobacterial arylamineN-acetyltransferase (NAT) [3]. NAT fromM. tuberculosis (TBNAT) was found to
be essential for intracellular survival and plays an important role in lipid metabolism [4]. During latent
infection, cholesterol plays a key role in M. tuberculosis persistence inside macrophages. NAT is
encoded in the cholesterol sterol-ring degradation gene cluster [5,6], and inhibitors explored [5,7,8]
against the recombinant enzyme validated NAT as a novel therapeutic target for designing new
antituberculosis drugs.
Nitro-containing heterocyclic compounds are promising for further investigation of their
antituberculosis potential, as they are currently predominant in the TB clinical drug trial pipeline.
Interestingly, the recently approved nitroheterocyclic drug, pretomanid to treat drug-resistant TB
and other nitroheterocyclic clinical candidates: delamanid, nitazoxanide, macozinone (PBTZ-196)
and BTZ-043 exhibit diverse mechanisms of action. Pretomanid and delamanid are mycobacterial
mycolic acid biosynthesis inhibitors and are also capable of poisoning cells by generating
reactive oxygen species. Nitazoxanide disrupts the membrane potential and pH homeostasis,
whereas macozinone and BTZ-043 inhibit arabinogalactan synthesis by forming a covalent adduct with
the decaprenylphosphoryl-ß-D-ribose-2′-epimerase (DprE1) enzyme [9]. Therefore, the exploration of
diverse mechanisms of action for nitroheterocyclic compounds is justified. We have previously worked
on developing 5-nitrofuran derivatives having antituberculosis potential [10]; the three most potent
molecules of the series, depicted in Figure 1, based on the resazurin microtiter assay (REMA) assay
results against M. tuberculosis H37Rv, were selected for further whole-cell phenotypic evaluation and
target identification.
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2. Results and Discussion
The selected molecules were evaluated against M. tuberculosis H37Rv using an agar-based
high-throughput spot culture inhibition (HT-SPOTi) assay to validate their potential to inhibit the
growth of tubercle bacilli, which was also determined, independently, using a broth-culture based
REMA assay [10]. The molecules were also evaluated against other bacterial strains, multidrug-resistant
M. tuberculosis, Mycobacterium bovis BCG, Mycobacterium aurum, Escherichia coli and Staphylococcus
aureus, and the respective minimum inhibitory concentration (MIC) values are provided in Table 1.
Compound 2 was found to be most potent against M. tuberculosis H37Rv, with an MIC of 0.031 mg/L,
and exhibited a lower MIC than the three first-line antituberculosis drugs (isoniazid, rifampicin and
ethambutol) and pretomanid, a drug used to treat drug-resistant TB. Both compounds 1 and 2
substituted with alicyclic amines, i.e., 4-piperidino and 4-morpholino, respectively, exhibited higher
activity against M. tuberculosis H37Rv than compound 3 with the aliphatic amino substituent, i.e.,
4-diethylamino. However, compound 3 with a MIC of 0.488 mg/L against the MDR-TB strain was
more potent than compounds 1, 2 and ethambutol and equipotent to pretomanid. These compounds
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showed no activity against the fast-growing mycobacterium M. aurum up to a 500 mg/L concentration.
Compounds 1 and 2 were found to be inactive against both representative Gram-negative and
Gram-positive strains, E. coli and S. aureus, respectively, while compound 3 showed some activity,
but it was insignificant when compared with its activity against the slow-growing mycobacterial
strains. Thus, the molecules were selective towards slow-growing mycobacteria M. tuberculosis
(drug-sensitive and multidrug-resistant) and M. bovis BCG. The use of broad-spectrum antimicrobial
agents often attributes to the development of resistance and cross-resistance, hence, the selectivity of
the compounds against mycobacteria may prove advantageous in tackling the challenge. It could
be inferred that the presence of an aliphatic amine substituent, i.e., 4-diethylamino in compound 3,
made the derivatives less selective towards slow-growing mycobacteria when compared to the other
alicyclic amine substituent-containing derivatives, compounds 1 and 2.
Table 1. Minimum inhibitory concentrations (MICs) of the derivatives and drug standards against
different species of bacteria, growth inhibitory concentrations (GICs) for cell lines and half-maximal
inhibitory concentration (IC50) for MMNAT.
Compound
MIC (mg/L) GIC (mg/L) IC50 (µM)(mg/L)
Mtb
H37Rv MDR-TB
Mycobacterium
bovis BCG
Mycobacterium
aurum
Escherichia
coli
Staphylococcus
aureus
THP-1 Cell
Line
RAW 264.7
Cell Line MMNAT
1 0.244 0.976 0.06 NAa NAa NAa 62.5 125 0.207(0.068)
2 0.031 1.953 0.0075 NAa NAa NAa 62.5 125 0.269(0.088)
3 0.488 0.488 0.03 NAa 250 62.5 15.6 31.25 0.134(0.042)
Isoniazid 0.80 NAa 0.625 1.25 ND ND NAa NAa NAb
Rifampicin 0.125 NAa 0.50 # 0.40 # ND ND ND ND NAb
Ethambutol 2.00 8.00 2.00 # 0.10 # ND ND ND ND NAb
Pretomanid 0.061 0.488 ND ND ND ND ND ND NAb
Ampicillin ND ND NAa ND 2.00 0.125 ND ND ND
Methotrexate NAa 250 500 ND ND ND 0.975 0.122 ND
Mtb: Mycobacterium tuberculosis, MDR-TB: multidrug-resistant M. tuberculosis, ND: not determined, NAa: not active
until 500 mg/L concentration, NAb: does not exhibit 50% inhibition, i.e., IC50 against M. marinum arylamine
N-acetyltransferase (MMNAT) up to 1 µM concentration and # MICs from reference Gupta and Bhakta, 2012.
The cytotoxic potential of the compounds was evaluated against the two cell lines:
human monocyte cell line (THP-1) and murine macrophage cell line (RAW 264.7); their respective
growth inhibitory concentration (GIC) values are provided in Table 1. The compounds showed low
cytotoxicity in comparison to their activities against slow-growing mycobacteria. Compounds 1 and
2 with alicyclic amine substituents showed lower cytotoxicity against both THP-1 and RAW 264.7
cell lines when compared to compound 3 with an aliphatic amine. For a better understanding of the
selectivity of the molecules towards mycobacteria, the selectivity index (SI) of the compounds with
respect to the slow-growing mycobacterial strains and THP-1 and RAW 264.7 cell line are shown in
Table 2. The compounds exhibited excellent selectivity towards mycobacteria than the respective
cell lines, with SIs ranging from 32 to as high as 16,997. The ability of the compounds to inhibit
mycobacteria within macrophages was assessed using an intracellular infection model of M. bovis BCG
infected in THP-1 macrophages. Amongst the three compounds selected, only compound 1 was found
to be active at 4×MIC with an ex vivo MIC of 0.24 mg/L. The standard drug used for this study was
isoniazid, which showed an ex vivo MIC of 1.25 mg/L, i.e., 2×MIC. Thus, compound 1 was found to be
more potent than isoniazid in killing intracellular M. bovis BCG. It will be interesting to further evaluate
the potential of these compounds and to measure their potency to penetrate the caseous tuberculosis
lesions, which harbour the persistent bacterial subpopulation, by a caseum binding assay [11].
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Table 2. Selectivity indices of the derivatives (cell line vs. mycobacteria).
Compound
SI
THP-1 RAW 264.7
Mtb H37Rv MDR-TB M. bovis BCG Mtb H37Rv MDR-TB M. bovis BCG
1 256 64 1042 512 128 2083
2 2016 32 8333 4032 64 16997
3 32 32 520 64 64 1042
Mtb: M. tuberculosis, MDR-TB: multidrug-resistant M. tuberculosis. The selectivity index (SI) was calculated by
dividing the GIC for the cell line by the MIC for the bacteria; the SI was not calculated with respect to M. aurum,
E. coli and S. aureus, as the compounds are inactive or showed low activity against the same.
The exploration of molecules that can inhibit novel TB drug targets is crucial for discovering
agents for the effective treatment of drug-resistant TB. NAT is a novel druggable enzyme in
M. tuberculosis involved in cell wall lipid metabolism and the detoxification of by-products of cholesterol
metabolism [12]. Thus, it is a prospective drug target for developing new antituberculosis drugs.
The derivatives were initially docked in M. tuberculosis arylamine N-acetyltransferase (TBNAT) (PDB:
4BGF), and then, their binding energies were assessed using molecular mechanics energies combined
with generalized Born and surface area continuum solvation (MM-GBSA) to comprehend their possible
interaction with the enzyme and their binding affinities. The compounds 1, 2 and 3 exhibited extra
precision GLIDE scores (XP g scores) of −3.788, −4.907 and −4.914 and MM-GBSA binding energy
(dG bind) scores of −67.001 kcal/mol, −64.833 kcal/mol and −66.757 kcal/mol, respectively. The more
negative XP g score and dG bind score indicate that the molecule binds better to the drug-target protein.
There is no drug that is known to mechanistically inhibit NAT, hence, a comparative standard drug
is not represented in Figure 2. On the other hand, the docking of the substrate hydralazine, along
with the derivatives, are depicted in Figure 2. Hydralazine showed an XP g score of −6.423 and a
dG bind score of −41.543 kcal/mol. The derivatives showed less negative g scores than the substrate
hydralazine but showed better binding energies. The low XP g score shown by compound 1 may
be attributed to a lack of interaction with His 110 (a residue of the NAT catalytic triad), whereas the
high XP g score shown by hydralazine may be attributed to the two interactions it has with His 110,
one hydrogen-bonding interaction and one pi-pi-stacking interaction. Thus, His 110 could be an
important residue for TBNAT binding.
The recombinant TBNAT enzyme is difficult to express in the soluble and active forms.
The recombinant Mycobacterium marinumN-acetyltransferase (MMNAT) with 73% amino acid sequence
identity is considered as the best available model for TBNAT [13,14]. Recombinant MMNAT was
chosen for assessing the ability of the derivatives to inhibit mycobacterial NAT and exhibits high
in vitro enzyme activity. All the amino acid residues within the binding pocket of mycobacterial NATs
are either conserved or conservatively substituted [15]. Furthermore, both TBNAT and MMNAT show
identical configuration of the catalytic triad (Cys70, His110 and Asp127), as reported by Abuhammad et
al. [16]. The preliminary evaluation of the compounds showed that the compounds were good MMNAT
inhibitors, with compound 3 being the most potent MMNAT inhibitory with a half-maximal inhibitory
concentration (IC50) of 0.134 µM. The other two compounds 1 and 2 also showed good inhibition of
MMNAT, with IC50 of 0.207 µM and 0.269 µM, respectively. As the compounds do not drastically
differ from one another, reasons that could account for the disparity between the antimycobacterial
activity and NAT enzyme inhibition need to be considered. As NAT plays a pivotal role in isoniazid
metabolism/detoxification, these molecules being NAT inhibitors could also be considered hits in the
development of adjunctive antituberculosis therapy to increase the efficacy of isoniazid by decreasing
its metabolism by NAT.
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3. aterials and Methods
3.1. Bacterial Strains and Cell Lines
M. tuberculosis H37Rv (ATCC 25618), multidrug-resistant M. tuberculosis Peru isolate (isolate from
a Peruvian patient, resistant to isoniazid and rifampicin) [17], M. bovis BCG (ATCC 35734), M. aurum
(NCTC 10437), E. coli (NCTC 10538), S. aureus (ATCC 25923), human THP-1 cell line (ATCC TIB202)
and murine RAW 264.7 cell line (ATCC TIB71) were used in this study. All cultures, bacterial and
eukaryotic, we e passaged at least twice before performing assays and were used while they were in
the logarithmic phase of growth.
3.2. Compounds
The derivatives evaluated in this study were chemically synthesized; their synthesis has been
previously reported by us [10]. The control drugs used in this study, isoniazid, rifampicin, ethambutol,
pretomanid (PA-824), ampicillin and methotrexate, were procured from Sigma Aldrich, London, UK.
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3.3. Evaluation of Antibacterial Potential Using High-throughput Spot Culture Growth Inhibition
(HT-SPOTi) Assay
The compounds were analyzed using HT-SPOTi, as described previously [18]. Briefly, the compounds
were dissolved in dimethyl sulfoxide, DMSO (Sigma Aldrich, London, UK) to achieve a concentration
of 50 mg/mL. A range (50-0.048 mg/mL) of compound concentrations was obtained by performing a
two-fold serial dilution in DMSO in sterile 96-well subskirted microtiter plates. A wider concentration
range (50-0.000024 mg/mL) of the drug ampicillin was sampled against S. aureus. Two microliters of
each dilution was added to a well in the 96-well flat-bottomed plate, to which 200 µL of agar-based
media (at 65 ◦C) was added using a Multidrop™ Combi Reagent Dispenser (Thermo Fisher Scientific,
London, UK). Middlebrook 7H10 agar (Becton Dickinson, London, UK) supplemented with 10% (v/v)
oleic acid-albumin-dextrose-catalase (OADC) (Fisher Scientific, London, UK) and 0.5% (v/v) glycerol
(Sigma Aldrich, London, UK) was used for mycobacterial species, whereas Luria-Bertani (LB) agar
(Sigma Aldrich, London, UK) was used for E. coli and S. aureus. The plates were cooled to room
temperature (RT) and 2 µL of diluted bacterial suspension, containing approximately 2 × 103 bacilli,
was spotted on each well. E. coli and S. aureus were incubated at 37 ◦C for 16 h, M. aurum at 35 ◦C
for 5 days, M. bovis BCG and multidrug-resistant M. tuberculosis Peru isolate at 37 ◦C for 14 days.
The experiments were carried out in three biological replicates (n = 3). The colonies/spot-culture
growths were visually observed after the required incubation period. The lowest concentration of the
compounds being tested at which no growth of bacteria was observed was reported as its MIC against
the corresponding bacteria [19–21].
3.4. Cytotoxicity Assay
The cytotoxicity of the compounds against human monocyte THP-1 and murine macrophage RAW
264.7 cell lines was performed using a 96-well plate resazurin assay, as described previously [20,22].
The compounds were serially diluted (two-fold) with RPMI-1640 media (Fisher Scientific, London, UK)
containing 10% fetal bovine serum (FBS) (Fisher Scientific, London, UK) in a final volume of 100 µL to
achieve a concentration range of 500-0.48 µg/mL. A serial dilution to achieve a concentration range
of 500-0.00024 µg/mL was carried out only for the evaluation of the cytotoxic drug, methotrexate,
which was used as a positive control in the experiment. Each compound was tested in triplicate. In each
well, 100 µL THP-1/RAW 264.7 cells (5 × 105 cells/mL) was added, and the plates were incubated in a
humidified CO2 incubator at 37 ◦C. Following a 48 h incubation period, the wells were washed twice
with 1× phosphate-buffered saline (PBS) (Fisher Scientific, London, UK). As undifferentiated THP-1
cells are nonadherent, the plates were centrifuged (1000× g, 2 min) between each wash. Finally, 170 µL
of fresh RPMI-1640 with 10% FBS was added to each well, followed by 30 µL of freshly prepared 0.01%
resazurin solution (Sigma Aldrich, London, UK), and the plates were incubated overnight (16 h) under
the conditions mentioned above. The experiments were carried out in three biological replicates (n = 3).
At the end of the incubation period, the color of the media in each well was observed. A color change
from blue to pink indicated active respiratory processes in live cells. The lowest concentration of the
compound at which no viable eukaryotic cells were detected (blue media) was reported as the GIC.
3.5. Intracellular Survival Assay
The intracellular survival of mycobacteria was assessed using the M. bovis BCG infected in
THP-1 macrophages model. The THP-1 monocyte cells (2 × 105 cells/well) were differentiated into
macrophages using 100 nM phorbol 12-myristate 13-acetate (PMA) (Sigma Aldrich, London, UK) in
RPMI-1640 (Fisher Scientific, London, UK) containing 10% fetal bovine serum (FBS) (Fisher Scientific,
London, UK) in 24-well plates and incubated at 37 ◦C, 5% CO2 for 48 h. After the 48 h incubation,
the media was aspirated out of the well, and the macrophages were washed twice with RPMI-1640
containing 10% FBS. The macrophages were infected with M. bovis BCG to achieve a multiplicity
of infection (MOI) of 10:1 and were incubated at 37◦C, 5% CO2 for 3 h. After the infection stage,
the culture was washed with RPMI-1640 twice and incubated for 48 h with different concentrations of
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the compounds (4×, 2×, 1×, 0.5× and 0.25×MIC) in RPMI-1640 media containing 10% FBS. Following
the incubation, the cells were washed twice with RPMI-1640 and lysed in 500 µL of sterile distilled
water at room temperature (RT) for 10 min. The lysed cells were centrifuged 16,000× g for 10 min at RT.
They were resuspended into 50 µL of sterile distilled water, and then, 5 µL was spotted onto the 24-well
plates containing Middlebrook 7H10 agar containing 10% (v/v) of OADC supplement. The plates were
incubated at 37 ◦C for 14 days, following which, they were checked for the growth of bacterial colonies
to determine intracellular survival. The experiment was carried out in three biological replicates
(n = 3) [23,24].
3.6. Molecular Docking and MM-GBSA of the Molecules
Docking studies were carried out using a Grid-based Ligand Docking with Energetics (GLIDE)
module of Maestro molecular modelling suite, Schrödinger LLC, NY. The protein structure PDB code:
4BGF for TBNAT was retrieved from Protein Data Bank (www.rcsb.com) and was subjected to protein
preparation. The protein was energy-minimized until the root mean square deviation (RMSD) of 0.3 Å
using the imperf tool of the protein preparation wizard in Maestro, and the fully prepared protein
was analyzed using a Ramachandran plot. The receptor grid was generated using the centroid of the
Phe 130 residue, as the PDB of the protein did not contain a co-crystalized ligand. The ligands were
prepared using Ligprep, where appropriate hydrogens were added to all structures, and subsequently,
energy minimization was carried out using the OPLS-2005 force field with a constant dielectric of
1.0 [25]. The ligands were docked using the extra-precision (XP) mode of the GLIDE module. The more
negative the XP g score, the better is the docking of the molecule in the receptor protein [26].
MM-GBSA estimates the free energy of the binding of small ligands to the biological
macromolecules. The more negative the dG bind score, which is expressed in kcal/mol, the better is
the ligand-binding affinity with the receptor. A constraint of 5 Å flexibility of the protein around the
ligand was applied for the study [27].
3.7. Estimation of Inhibition against Recombinant Mycobacterium Marinum N-acetyl Transferase (MMNAT)
MMNAT was expressed in E. coli BL21(DE3)pLysS cells transformed with the pET28b(+)
vector containing the nat gene (MMAR_5055) insert and purified using nickel (Ni2+) ion affinity
chromatography, as described previously [13,28]. Ten microliters of MMNAT enzyme (0.1 µg/µL), i.e.,
1 µg of the enzyme in each well, was incubated with 45 µL of hydralazine (Sigma Aldrich, London,
UK) (final concentration: 450 µM) for 5 min at RT. One microliter of DMSO solution containing the
compound was added to achieve the appropriate concentration. Forty microliters of acetyl CoA (Sigma
Aldrich, London, UK) (final concentration: 400 µM) was added to each well to start the reaction.
The reaction mixture was incubated for 20 min at RT. Twenty-five microliters of stop solution, i.e.,
5 mM 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB) (Sigma Aldrich, London, UK) solution in 6.4 M
guanidine HCl (Sigma Aldrich, London, UK) (pH 8), was added to all the wells. The plates were read
at 405 nm. The experiment was carried out in two biological replicates (n = 2). There were two controls
set up: one with no enzyme (0% enzyme activity) and one with no inhibitor (100% enzyme activity).
Percentage of inhibition was calculated using a negative control (0% enzyme activity) and enzyme
reaction (100% enzyme activity), which were further used to generate a linear regression from which
IC50 of the compounds was calculated through extrapolation (Supplementary Materials) [7,29].
4. Conclusions
This study identified highly potent, selective and mycobactericidal hits with a novel mechanism
of action. Compound 2 was found to be more potent than the three first-line TB drugs (isoniazid,
rifampicin and ethambutol) and pretomanid against M. tuberculosis H37Rv. Compound 3 exhibited a
higher activity than ethambutol and was equipotent to pretomanid against MDR-TB. The compounds
exhibited a bactericidal mode of action when evaluated against M. bovis BCG. Compound 1 was
effective in inhibiting M. bovis BCG within THP-1 macrophages and could be considered for evaluation
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in a dormant TB model. The compounds showed selectivity towards M. tuberculosis H37Rv, MDR-TB
and M. bovis BCG when compared to Gram-positive and Gram-negative bacteria. The compounds
showed low cytotoxicity and excellent selectivity towards mycobacteria when compared to THP-1 and
RAW 264.7 cell lines. We, for the first time, have identified 5-nitrofuran as a prospective scaffold for
mycobacterial NAT inhibition, and it could be used as a basis to design mycobacterial NAT inhibitors
in the future. The compounds being potent and selective antimycobacterial agents could be further
studied for their prospects of being developed into preclinical/clinical candidate(s).
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/9/7/368/s1.
Figure S1: Enzyme inhibition plots of compounds 1, 2 and 3 against M. marinum NAT.
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